1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Mmunomedics Technology
1.2.3 Immunogen Technology
1.2.4 Seattle Genetics Technology
1.2.5 Others
1.3 Market by Application
1.3.1 Global Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Biotechnology Companies
1.3.3 Specialized Cancer Centers
1.3.4 Biopharmaceutical Companies
1.3.5 Academic Research Institutes
1.3.6 Hospitals
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered 2 Global Growth Trends
2.1 Global Antibody Drug Conjugate (ADC) Drug Market Perspective (2017-2028)
2.2 Antibody Drug Conjugate (ADC) Drug Growth Trends by Region
2.2.1 Antibody Drug Conjugate (ADC) Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Antibody Drug Conjugate (ADC) Drug Historic Market Size by Region (2017-2022)
2.2.3 Antibody Drug Conjugate (ADC) Drug Forecasted Market Size by Region (2023-2028)
2.3 Antibody Drug Conjugate (ADC) Drug Market Dynamics
2.3.1 Antibody Drug Conjugate (ADC) Drug Industry Trends
2.3.2 Antibody Drug Conjugate (ADC) Drug Market Drivers
2.3.3 Antibody Drug Conjugate (ADC) Drug Market Challenges
2.3.4 Antibody Drug Conjugate (ADC) Drug Market Restraints 3 Competition Landscape by Key Players
3.1 Global Top Antibody Drug Conjugate (ADC) Drug Players by Revenue
3.1.1 Global Top Antibody Drug Conjugate (ADC) Drug Players by Revenue (2017-2022)
3.1.2 Global Antibody Drug Conjugate (ADC) Drug Revenue Market Share by Players (2017-2022)
3.2 Global Antibody Drug Conjugate (ADC) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antibody Drug Conjugate (ADC) Drug Revenue
3.4 Global Antibody Drug Conjugate (ADC) Drug Market Concentration Ratio
3.4.1 Global Antibody Drug Conjugate (ADC) Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugate (ADC) Drug Revenue in 2021
3.5 Antibody Drug Conjugate (ADC) Drug Key Players Head office and Area Served
3.6 Key Players Antibody Drug Conjugate (ADC) Drug Product Solution and Service
3.7 Date of Enter into Antibody Drug Conjugate (ADC) Drug Market
3.8 Mergers & Acquisitions, Expansion Plans 4 Antibody Drug Conjugate (ADC) Drug Breakdown Data by Type
4.1 Global Antibody Drug Conjugate (ADC) Drug Historic Market Size by Type (2017-2022)
4.2 Global Antibody Drug Conjugate (ADC) Drug Forecasted Market Size by Type (2023-2028) 5 Antibody Drug Conjugate (ADC) Drug Breakdown Data by Application
5.1 Global Antibody Drug Conjugate (ADC) Drug Historic Market Size by Application (2017-2022)
5.2 Global Antibody Drug Conjugate (ADC) Drug Forecasted Market Size by Application (2023-2028) 6 North America
6.1 North America Antibody Drug Conjugate (ADC) Drug Market Size (2017-2028)
6.2 North America Antibody Drug Conjugate (ADC) Drug Market Size by Type
6.2.1 North America Antibody Drug Conjugate (ADC) Drug Market Size by Type (2017-2022)
6.2.2 North America Antibody Drug Conjugate (ADC) Drug Market Size by Type (2023-2028)
6.2.3 North America Antibody Drug Conjugate (ADC) Drug Market Share by Type (2017-2028)
6.3 North America Antibody Drug Conjugate (ADC) Drug Market Size by Application
6.3.1 North America Antibody Drug Conjugate (ADC) Drug Market Size by Application (2017-2022)
6.3.2 North America Antibody Drug Conjugate (ADC) Drug Market Size by Application (2023-2028)
6.3.3 North America Antibody Drug Conjugate (ADC) Drug Market Share by Application (2017-2028)
6.4 North America Antibody Drug Conjugate (ADC) Drug Market Size by Country
6.4.1 North America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2017-2022)
6.4.2 North America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada 7 Europe
7.1 Europe Antibody Drug Conjugate (ADC) Drug Market Size (2017-2028)
7.2 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Type
7.2.1 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Type (2017-2022)
7.2.2 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Type (2023-2028)
7.2.3 Europe Antibody Drug Conjugate (ADC) Drug Market Share by Type (2017-2028)
7.3 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Application
7.3.1 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Application (2017-2022)
7.3.2 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Application (2023-2028)
7.3.3 Europe Antibody Drug Conjugate (ADC) Drug Market Share by Application (2017-2028)
7.4 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Country
7.4.1 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Country (2017-2022)
7.4.2 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries 8 Asia-Pacific
8.1 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size (2017-2028)
8.2 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Type
8.2.1 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Share by Type (2017-2028)
8.3 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Application
8.3.1 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Share by Application (2017-2028)
8.4 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Region
8.4.1 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia 9 Latin America
9.1 Latin America Antibody Drug Conjugate (ADC) Drug Market Size (2017-2028)
9.2 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Type
9.2.1 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Type (2017-2022)
9.2.2 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Type (2023-2028)
9.2.3 Latin America Antibody Drug Conjugate (ADC) Drug Market Share by Type (2017-2028)
9.3 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Application
9.3.1 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Application (2017-2022)
9.3.2 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Application (2023-2028)
9.3.3 Latin America Antibody Drug Conjugate (ADC) Drug Market Share by Application (2017-2028)
9.4 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Country
9.4.1 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2017-2022)
9.4.2 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil 10 Middle East & Africa
10.1 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size (2017-2028)
10.2 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Type
10.2.1 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Share by Type (2017-2028)
10.3 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Application
10.3.1 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Share by Application (2017-2028)
10.4 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Country
10.4.1 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE 11 Key Players Profiles
11.1 Oxford Bio Therapeutics
11.1.1 Oxford Bio Therapeutics Company Details
11.1.2 Oxford Bio Therapeutics Business Overview
11.1.3 Oxford Bio Therapeutics Antibody Drug Conjugate (ADC) Drug Introduction
11.1.4 Oxford Bio Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.1.5 Oxford Bio Therapeutics Recent Developments
11.2 Synthon
11.2.1 Synthon Company Details
11.2.2 Synthon Business Overview
11.2.3 Synthon Antibody Drug Conjugate (ADC) Drug Introduction
11.2.4 Synthon Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.2.5 Synthon Recent Developments
11.3 Progenics Pharmaceuticals
11.3.1 Progenics Pharmaceuticals Company Details
11.3.2 Progenics Pharmaceuticals Business Overview
11.3.3 Progenics Pharmaceuticals Antibody Drug Conjugate (ADC) Drug Introduction
11.3.4 Progenics Pharmaceuticals Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.3.5 Progenics Pharmaceuticals Recent Developments
11.4 Bayer HealthCare
11.4.1 Bayer HealthCare Company Details
11.4.2 Bayer HealthCare Business Overview
11.4.3 Bayer HealthCare Antibody Drug Conjugate (ADC) Drug Introduction
11.4.4 Bayer HealthCare Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.4.5 Bayer HealthCare Recent Developments
11.5 Millennium Pharmaceuticals
11.5.1 Millennium Pharmaceuticals Company Details
11.5.2 Millennium Pharmaceuticals Business Overview
11.5.3 Millennium Pharmaceuticals Antibody Drug Conjugate (ADC) Drug Introduction
11.5.4 Millennium Pharmaceuticals Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.5.5 Millennium Pharmaceuticals Recent Developments
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Antibody Drug Conjugate (ADC) Drug Introduction
11.6.4 Pfizer Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.6.5 Pfizer Recent Developments
11.7 Concortis Bio therapeutics
11.7.1 Concortis Bio therapeutics Company Details
11.7.2 Concortis Bio therapeutics Business Overview
11.7.3 Concortis Bio therapeutics Antibody Drug Conjugate (ADC) Drug Introduction
11.7.4 Concortis Bio therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.7.5 Concortis Bio therapeutics Recent Developments
11.8 Roche Holding AG
11.8.1 Roche Holding AG Company Details
11.8.2 Roche Holding AG Business Overview
11.8.3 Roche Holding AG Antibody Drug Conjugate (ADC) Drug Introduction
11.8.4 Roche Holding AG Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.8.5 Roche Holding AG Recent Developments
11.9 Seattle Genetics
11.9.1 Seattle Genetics Company Details
11.9.2 Seattle Genetics Business Overview
11.9.3 Seattle Genetics Antibody Drug Conjugate (ADC) Drug Introduction
11.9.4 Seattle Genetics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.9.5 Seattle Genetics Recent Developments
11.10 Heidelberg Pharma
11.10.1 Heidelberg Pharma Company Details
11.10.2 Heidelberg Pharma Business Overview
11.10.3 Heidelberg Pharma Antibody Drug Conjugate (ADC) Drug Introduction
11.10.4 Heidelberg Pharma Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.10.5 Heidelberg Pharma Recent Developments
11.11 Mersana Therapeutics
11.11.1 Mersana Therapeutics Company Details
11.11.2 Mersana Therapeutics Business Overview
11.11.3 Mersana Therapeutics Antibody Drug Conjugate (ADC) Drug Introduction
11.11.4 Mersana Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.11.5 Mersana Therapeutics Recent Developments
11.12 Astellas Pharma/Agensys
11.12.1 Astellas Pharma/Agensys Company Details
11.12.2 Astellas Pharma/Agensys Business Overview
11.12.3 Astellas Pharma/Agensys Antibody Drug Conjugate (ADC) Drug Introduction
11.12.4 Astellas Pharma/Agensys Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.12.5 Astellas Pharma/Agensys Recent Developments
11.13 AbbVie Inc
11.13.1 AbbVie Inc Company Details
11.13.2 AbbVie Inc Business Overview
11.13.3 AbbVie Inc Antibody Drug Conjugate (ADC) Drug Introduction
11.13.4 AbbVie Inc Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.13.5 AbbVie Inc Recent Developments
11.14 Celldex Therapeutics
11.14.1 Celldex Therapeutics Company Details
11.14.2 Celldex Therapeutics Business Overview
11.14.3 Celldex Therapeutics Antibody Drug Conjugate (ADC) Drug Introduction
11.14.4 Celldex Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.14.5 Celldex Therapeutics Recent Developments
11.15 Immunomedics
11.15.1 Immunomedics Company Details
11.15.2 Immunomedics Business Overview
11.15.3 Immunomedics Antibody Drug Conjugate (ADC) Drug Introduction
11.15.4 Immunomedics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.15.5 Immunomedics Recent Developments
11.16 Agensys
11.16.1 Agensys Company Details
11.16.2 Agensys Business Overview
11.16.3 Agensys Antibody Drug Conjugate (ADC) Drug Introduction
11.16.4 Agensys Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.16.5 Agensys Recent Developments
11.17 Genentech
11.17.1 Genentech Company Details
11.17.2 Genentech Business Overview
11.17.3 Genentech Antibody Drug Conjugate (ADC) Drug Introduction
11.17.4 Genentech Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.17.5 Genentech Recent Developments
11.18 ImmunoGen
11.18.1 ImmunoGen Company Details
11.18.2 ImmunoGen Business Overview
11.18.3 ImmunoGen Antibody Drug Conjugate (ADC) Drug Introduction
11.18.4 ImmunoGen Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.18.5 ImmunoGen Recent Developments
11.19 Sanofi
11.19.1 Sanofi Company Details
11.19.2 Sanofi Business Overview
11.19.3 Sanofi Antibody Drug Conjugate (ADC) Drug Introduction
11.19.4 Sanofi Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.19.5 Sanofi Recent Developments
11.20 Genmab
11.20.1 Genmab Company Details
11.20.2 Genmab Business Overview
11.20.3 Genmab Antibody Drug Conjugate (ADC) Drug Introduction
11.20.4 Genmab Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.20.5 Genmab Recent Developments
11.21 Amgen
11.21.1 Amgen Company Details
11.21.2 Amgen Business Overview
11.21.3 Amgen Antibody Drug Conjugate (ADC) Drug Introduction
11.21.4 Amgen Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.21.5 Amgen Recent Developments
11.22 Novartis
11.22.1 Novartis Company Details
11.22.2 Novartis Business Overview
11.22.3 Novartis Antibody Drug Conjugate (ADC) Drug Introduction
11.22.4 Novartis Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.22.5 Novartis Recent Developments
11.23 Eli Lilly
11.23.1 Eli Lilly Company Details
11.23.2 Eli Lilly Business Overview
11.23.3 Eli Lilly Antibody Drug Conjugate (ADC) Drug Introduction
11.23.4 Eli Lilly Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)
11.23.5 Eli Lilly Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
